Also, maybe the presentation wasn't clear that we've actually had our cells in packs driving cars for several months. Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) * 10X Genomics Inc (NASDAQ: TXG) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Beigene Ltd (NASDAQ: BGNE) * Cardiff Oncology Inc (NASDAQ: CRDF) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Evogene Ltd (NASDAQ: EVGN) * Fate Therapeutics Inc (NASDAQ: FATE) * Guardant Health Inc (NASDAQ: GH) * InVitae Corp (NYSE: NVTA) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Kura Oncology Inc (NASDAQ: KURA) * Lantern Pharma Inc. (NASDAQ: LTRN) * Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Prelude Therapeutics Incorporated (NASDAQ: PRLD) (listed Thursday) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Shockwave Medical Inc (NASDAQ: SWAV * Turning Point Therapeutics Inc (NASDAQ: T)PTX) * Twist Bioscience Corp (NASDAQ: TWST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 28) * Abeona Therapeutics Inc (NASDAQ: ABEO) (announced departure of CEO and board members stepping down) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Gritstone Oncology Inc (NASDAQ: GRTS) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Neos Therapeutics Inc (NASDAQ: NEOS) * Odonate Therapeutics Inc (NASDAQ: ODT) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) (announced EMA's Priority Medicines designation for gene therapy candidate OTL-203 in the treatment of mucopolysaccharidosis type I) * PainReform Ltd (NASDAQ: PRFX) * Radius Health Inc (NASDAQ: RDUS) * Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tricida Inc (NASDAQ: TCDA)Stocks In Focus Pfizer's Rheumatoid Arthritis Drug Gets Label Expansion Pfizer Inc. (NYSE: PFE) said the FDA approved two formulations -- a tablet and oral solution -- of Xeljanz for the treatment of children and adolescents 2 and older with active polyarticular course juvenile idiopathic arthritis.The company said Xeljanz 5mg tablets are immediately available, while the oral solution is expected to be available by the end of the first quarter of 2021.The stock was trading 0.3% higher to $36.50 premarket Tuesday.Sorrento Reports Positive Preclinical COVID-19 Antibody Data Sorrento Therapeutics Inc (NASDAQ: SRNE) announced preclinical data on COVI-GUARD, codenamed STI-1499, and COVI-AMG, codenamed STI-2020, neutralizing antibodies against SARS-CoV-2 as well as a D614G virus variant infection, showing that both demonstrated potent neutralizing activities against SARS-CoV-2 virus infection in preclinical models.STI-1499 nAb has been cleared by the FDA for a Phase 1 clinical trial in hospitalized COVID-19 patients. The broad antiviral activity could also allow the drug to be used against future novel viruses, in the analyst’s opinion. 9550 Firestone Blvd. Data Processors (or Service Providers) Data Processor (or Service Provider) means any natural or legal person who processes the data on behalf of the Data Controller. Learn more about who we are and book your next vacation at MGMResorts.com today.
On CNBC's "Mad Money Lightning Round," Jim Cramer said to a viewer he is right to buy Boeing Co (NYSE: BA). Casino.org revealed earlier this month that Las Vegas casino executives met to discuss potential safeguards for when their properties reopen, and such kiosks were considered. © 2020 Meruelo Group - All rights reserved. You can hold me to it.> > -- Elon Musk (@elonmusk) September 28, 2020SpaceX is considered to be one of the most valuable venture-backed businesses in the United States, with an estimated valuation above $46 billion as of August.Why It Matters: In March, Musk, who also leads Tesla Inc (NASDAQ: TSLA), said publicly that he was not considering an IPO for Starlink, saying, "We're thinking about that zero. ADA Statement
In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets... We’ve taken out the froth that had come into the market in certain [mega cap] names. This page informs you of our policies regarding the collection, use and disclosure of personal data when you use our Service and the choices you have associated with that data.